Optimizing uPAR-targeting radiopeptides for improved tissue distribution: progress towards radionuclide therapy
In view of a clinical translation, [<sup>177</sup>Lu]Lu-uPAR-11 emerged as the most favorable candidate. Future studies will, thus, focus on the therapeutic potential of [<sup>177</sup>Lu]Lu-uPAR-11 in tumor-bearing mice.
Authors
- Christian Vaccarin (ORCID: https://orcid.org/0000-0001-9876-7258)
- Roger Schibli (ORCID: https://orcid.org/0000-0002-1537-3833)
- Darja Beyer
- Xavier Deupí (ORCID: https://orcid.org/0000-0003-4572-9316)
- Johannes A. Schmid (ORCID: https://orcid.org/0000-0002-6586-3507)
- Cristina Mueller (ORCID: https://orcid.org/0000-0001-9357-9688)
- B. Klein
- Jathursa Jegathasan
- Shreshtha Behera
Institutions
- SIB Swiss Institute of Bioinformatics (CH)
- Paul Scherrer Institute (CH)
- ETH Zurich (CH)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2025-10-27
- DOI
- https://doi.org/10.1007/s00259-025-07602-7
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Science Foundation
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung